Americans face growing challenges affording healthcare. New data reveals a significant drop in those able to manage medical costs and acces...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

Alkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

The Guidance Document establishes, for the first time, a structured and standardised national framework for the screening, diagnosis, treat...

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Mankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and h...

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patien...

The expiry of a key patent for semaglutide in India opens doors for affordable weight-loss and diabetes drugs. Indian pharmaceutical compan...

With Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.

Mankind Pharma has launched an anti-diabetic product 'Dynaglipt' targeting the middle class and rural diabetic patients.

Drug firm Zydus Cadila has launched its generic Tenglyn tablets belonging to new class of oral anti-diabetic treatment drugs, Gliptins, in ...